Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study

Verruca Vulgaris Clinical Trial

Official title:

Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04793529
• Other study ID #: RC-2-3-2021
• Status: Completed
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: October 1, 2019

Study information

• Verified date: July 2023
• Source: Benha University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin D3. Subjects and Methods: This study included 60 patients with verrucae vulgaris subjected to intralesional injection of vitamin D3 at three weeks interval for a maximum of five sessions. Immunohistochemical assessment of involucrin was done before and after injection and compared to skin biopsies from 30 healthy individuals

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 1, 2019
• Est. primary completion date: October 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion criteria:

Patients with multiple verruca vulgaris Patients with with verrucae vulgaris with size more than 3 cm

Exclusion Criteria:

Patients with a past history of allergic response to vitamin D. Pregnant or lactating females. Hepatic patients. Renal patients. Patients with bleeding tendency.

Related Conditions & MeSH terms

• Involucrin
• Verruca Vulgaris
• Warts

Intervention

Drug:
• Cholecalciferol
Cholecalciferol injection

Locations

Country	Name	City	State
Egypt	Essam Mohamed El-sayed Akl	Banha

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resolution of verrucae	Decrease of verrucae size Decrease of verrucae number	3 months
Secondary	Involucrin expression	Change of expression pattern of involucrin by immunohistochemical study Change of expression grade of involucrin by immunohistochemical study	3 months